Evidence map›Paper›PMID 22623743›Full record

ArticleScience translational medicine2012

Modeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis.

Rinat Sergeev, Caroline Colijn, Megan Murray, Ted Cohen

Abstract read
In one paragraph

Article in Science translational medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. The relative fitness of drug-resistantJournal of the Royal Society, Interface · 2018
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. First insights into circulating Mycobacterium tuberculosis complex lineages and drug resistance in Guinea.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2015
    Article
  15. Article
  16. How can mathematical models advance tuberculosis control in high HIV prevalence settings?The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2014
    Review
  17. Article
  18. Article
  19. Article
  20. Molecular biology of drug resistance in Mycobacterium tuberculosis.Current topics in microbiology and immunology · 2013
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Rinat SergeevDepartment of Medicine, Brigham and Women's Hospital, 641 Huntington Avenue, Boston, MA 02115, USA. rinat@theory.ioffe.ru
Caroline Colijn
Megan Murray
Ted Cohen

Funding

Understanding and controlling antibiotic resistanceU54GM088558 · NIGMS · HARVARD SCHOOL OF PUBLIC HEALTH · PI LIPSITCH, MARC · 2009 to 2018
$26.4M
Prevalence, risk factors and consequences of complex M. Tuberculosis infectionsDP2OD006663 · OD · BRIGHAM AND WOMEN'S HOSPITAL · PI COHEN, THEODORE H · 2010 to 2010
$2.7M
NIGMS NIH HHS U54 GM088558NIGMS NIH HHS U54GM088558.NIH HHS DP2 OD006663NIH HHS DP2OD006663
6 · The paper itself

Abstract

The emergence of highly drug-resistant tuberculosis (TB) and interactions between TB and HIV epidemics pose serious challenges for TB control. Previous researchers have presented several hypotheses for why HIV-coinfected TB patients may suffer an increased risk of drug-resistant TB (DRTB) compared to other TB patients. Although some studies have found a positive association between an individual's HIV status and his or her subsequent risk of multidrug-resistant TB (MDRTB), the observed individual-level relationship between HIV and DRTB varies substantially among settings. Here, we develop a modeling framework to explore the effect of HIV on the dynamics of DRTB. The model captures the acquisition of resistance to important classes of TB drugs, imposes fitness costs associated with resistance-conferring mutations, and allows for subsequent restoration of fitness because of compensatory mutations. Despite uncertainty in several key parameters, we demonstrate epidemic behavior that is robust over a range of assumptions. Whereas HIV facilitates the emergence of MDRTB within a community over several decades, HIV-seropositive individuals presenting with TB may, counterintuitively, be at lower risk of drug-resistant TB at early stages of the co-epidemic. This situation arises because many individuals with incident HIV infection will already harbor latent Mycobacterium tuberculosis infection acquired at an earlier time when drug resistance was less prevalent. We find that the rise of HIV can increase the prevalence of MDRTB within populations even as it lowers the average fitness of circulating MDRTB strains compared to similar populations unaffected by HIV. Preferential social mixing among individuals with similar HIV status and lower average CD4 counts among HIV-seropositive individuals further increase the expected burden of MDRTB. This model suggests that the individual-level association between HIV and drug-resistant forms of TB is dynamic, and therefore, cross-sectional studies that do not report a positive individual-level association will not provide assurance that HIV does not exacerbate the burden of resistant TB in the community.

Indexed as

Antitubercular AgentsHIV InfectionsHumansModels, TheoreticalMycobacterium tuberculosisTuberculosis, Multidrug-ResistantAntitubercular Agents

Identifiers

PMID22623743
PMCPMC3387814

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.